Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

202.18 -2.93 (-1.43%)

Streaming Delayed Price Updated: 10:03 AM EDT, Sep 15, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	167,859
Open	206.98
Bid (Size)	201.81 (200)
Ask (Size)	202.55 (400)
Prev. Close	205.11
Today's Range	201.44 - 207.00
52wk Range	42.18 - 224.31
Shares Outstanding	106,313,250
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

MarketBeat Week in Review – 09/07 - 09/11 ↗

September 12, 2026

Stocks fell this week on oil prices and Fed rate-hike expectations, though Oracle's earnings underscored AI infrastructure strength. MarketBeat analysts recap top stories on earnings, defense, AI, and...

Via MarketBeat

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 11, 2026

Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.

Via The Motley Fool

Performance

YTD	+155.9%	+155.9%
1 Month	-4.6%	-4.6%
3 Month	+26.3%	+26.3%
6 Month	+104.2%	+104.2%
1 Year	+337.6%	+337.6%

More News

Revolution Medicines Got Its Breakthrough—What Moves It Next? ↗

September 04, 2026

Via MarketBeat

Revolution Medicines (NASDAQ:RVMD) Misses Q2 Estimates, Yet FDA Accepts Daraxonrasib Application ↗

August 05, 2026

Via Chartmill

Revolution Medicines (NASDAQ:RVMD) Flashes Strong Technical Breakout Setup ↗

July 30, 2026

Via Chartmill

$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today ↗

September 04, 2026

Via Benzinga

Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer ↗

August 28, 2026

Via MarketBeat

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X? ↗

August 28, 2026

Via The Motley Fool

Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today ↗

August 26, 2026

Via Benzinga

Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't? ↗

August 25, 2026

Via The Motley Fool

GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity ↗

August 24, 2026

Via The Motley Fool

Meet the Vanguard ETF That's Crushing the S&P 500 and Nasdaq-100 Despite Not Owning Micron, Sandisk, or Any of the "Magnificent Seven" Stocks ↗

August 18, 2026

Via The Motley Fool

Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Via The Motley Fool

Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years ↗

August 07, 2026

Via Benzinga

Revolution Medicines Q2 Earnings Call Highlights ↗

August 06, 2026

Via MarketBeat

Billionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy? ↗

August 03, 2026

Via The Motley Fool

Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock ↗

August 02, 2026

Via The Motley Fool

Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now ↗

July 29, 2026

Via The Motley Fool

This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on It ↗

July 17, 2026

Via The Motley Fool

Better Growth Buy: Axsome vs Revolution Medicines ↗

July 09, 2026

Via The Motley Fool

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

July 07, 2026

From Revolution Medicines, Inc.

Via GlobeNewswire

These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More ↗

July 06, 2026

Via The Motley Fool

Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy? ↗

July 05, 2026

Via The Motley Fool

Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd. ↗

July 01, 2026

Via The Motley Fool

Can Revolution Medicines Be a Game-Changer Stock? ↗

June 11, 2026

Via The Motley Fool

Frequently Asked Questions

Is Revolution Medicines, Inc. - Common Stock publicly traded?

Yes, Revolution Medicines, Inc. - Common Stock is publicly traded.

What exchange does Revolution Medicines, Inc. - Common Stock trade on?

Revolution Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Revolution Medicines, Inc. - Common Stock?

The ticker symbol for Revolution Medicines, Inc. - Common Stock is RVMD on the Nasdaq Stock Market

What is the current price of Revolution Medicines, Inc. - Common Stock?

The current price of Revolution Medicines, Inc. - Common Stock is 202.18

When was Revolution Medicines, Inc. - Common Stock last traded?

The last trade of Revolution Medicines, Inc. - Common Stock was at 09/15/26 10:03 AM ET

What is the market capitalization of Revolution Medicines, Inc. - Common Stock?

The market capitalization of Revolution Medicines, Inc. - Common Stock is 21.49B

How many shares of Revolution Medicines, Inc. - Common Stock are outstanding?

Revolution Medicines, Inc. - Common Stock has 21B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.